Anti-vascular endothelial growth factor (anti-VEGF) drugs like Lucentis (Ranibizumab), Avastin (Bevacizumab) and Eylea (Aflibercept) have revolutionized the treatment of retinal diseases like Wet AMD, Diabetic Macular Edema (DME), and Vein Occlusions with Macular Edema.
Lucentis is an antibody fragment derived from the parent antibody Avastin. All three drugs are specific for targeting and blocking VEGF, which triggers the growth and leakage of abnormal blood vessels (neovascularization). When this neovascularization occurs in the retina, especially the macula, this can lead to vision loss. All 3 drugs have been successful when injected into the vitreous cavity of the eye (intravitreally).